Sexual Function and Depressive Symptoms Among Female North American Medical Students

University of California Davis-Department of Urology, Sacramento, CA 95816, USA.
Journal of Sexual Medicine (Impact Factor: 3.15). 11/2010; 8(2):391-9. DOI: 10.1111/j.1743-6109.2010.02085.x
Source: PubMed

ABSTRACT Depression and sexual dysfunction are often comorbid.
We explored the relationship between sexuality, sexual dysfunction, and depressive symptoms in female medical students in North America.
Female North American medical students were invited to participate in an internet survey. The CES-D was utilized to screen for depressive symptoms and an abbreviated Spielberger State-Trait Anxiety Index (STAI) was used to quantify anxiety symptoms.
Subjects completed an ethnodemographic survey, a sexuality survey, and modified instruments for the quantification of sexual function (the Female Sexual Function Index [FSFI] and the Index of Sexual Life [ISL]). Multivariable logistic regression was used to explore the relationship between sexuality and depressive symptoms.
There were 1,241 female subjects with complete data on CES-D and STAI. Mean age was 25.4 years. Depressive symptoms (CES-D>16) were present in 46% of respondents and were more common in subjects with anxiety symptoms. Subjects who were Caucasian, younger than 28, heterosexual, and in a relationship were least likely to report depressive symptoms. High risk of female sexual dysfunction (HRFSD) was significantly associated with greater likelihood of depressive symptoms (odds ratio [OR] 2.25, P<0.001). After adjusting for ethnodemographic and sexual history factors, HRFSD remained significantly positively associated with depressive symptoms (OR 1.85, P<0.001). Analysis of FSFI and ISL domains indicated that depressive symptoms were most directly associated with worse orgasmic function, interference in sex life from stress and lack of partner, and lower general life satisfaction (P<0.05). Interestingly, greater ISL-sexual satisfaction was associated with greater odds of depressive symptoms (OR 1.40, P=0.01).
Depressive symptoms are common in female medical students. HRFSD is associated with depressive symptoms, although the relationship is complex when psychosocial factors are included in the multivariate model. Attention to sexuality factors from student health providers may enhance quality-of-life, academic achievement, and patient care.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We report surprising findings from a pilot study aimed at assessing the psychological price paid by female medical students who are also involved in serious romantic relationships. Sixty female medical students were assessed as to their depressive symptoms, level of self-criticism, sexual satisfaction, role commitment, and perceived rewards derived from their professional, marital, and domestic roles. The high levels of depressive symptoms found among participants in this study were the sole predictor of low sexual satisfaction. Professional role reward was positively associated with depressive symptoms. Consistent with the notion of multiple roles conflict among self-critical students, role commitment and reward in the professional and domestic domains interacted to predict depressive symptoms. Results suggest that female medical students involved in romantic relationships pay a high emotional price for their conflicting role demands.
    Psychiatry Interpersonal & Biological Processes 06/2012; 75(2):167-75. DOI:10.1521/psyc.2012.75.2.167 · 3.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Information regarding sexual dysfunction risk among young Latin American women is limited. Assess female sexual dysfunction (FSD) risk and associated factors in young Peruvian university women. This was a nested case-control study, using the Female Sexual Function Index (FSFI). Cases were defined as women with total FSFI scores at or below 26.55 (increased FSD risk). Demographic characteristics, gynecologic aspects, body mass index, mood disorders, substance abuse, and issues related to the couple, were also evaluated. Primary end point was assessment of FSD risk and associated factors. A total of 625 women were surveyed of which 409 (65.4%) were sexually active. The average total FSFI score was 27.2 ± 4.3. Overall, 39.9% were at higher risk for FSD. Multivariate analysis using a binary logistic regression model found that male premature ejaculation (odds ratios [OR]=2.47, 95% confidence interval [CI]: 1.27-4.77), oral emergency contraception use (OR=1.87, 95% CI: 1.04-3.38), good partner relationship (OR=0.24, 95% CI: 0.12-0.49), and length of relationship (≥3 years; OR=0.025, 95% CI: 0.013-0.05) were factors independently associated to a higher FSD risk (goodness of fit P=0.39). In this young university female population, FSD risk was high and associated to male and female factors.
    Journal of Sexual Medicine 06/2011; 8(6):1701-9. DOI:10.1111/j.1743-6109.2011.02259.x · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gepirone-extended release (ER) is effective in treating hypoactive sexual desire disorder (HSDD), as measured by the percent of females with HSDD that no longer met criteria for HSDD treatment. Another approach is to determine treatment effect on sexual desire using a recognized rating scale for sexual function. Because gepirone-ER has antidepressant and anxiolytic effects, investigation of these effects on sexual desire is appropriate. The aim of this study was to determine whether gepirone-ER has positive effects on sexual desire as measured by the DeRogatis Inventory of Sexual Function (DISF) in a post hoc analysis of 8- and 24-week studies and if this gepirone effect is independent of its antidepressant or anxiolytic activity. The main outcome measures used for this study were the Hamilton Depression Rating Scale (HAMD-25), change from baseline (CFB), and DISF CFB. Three hundred thirty-four women selected for depressive symptoms, not sexual dysfunction, received gepirone-ER (40-80 mg/day) in a controlled study of atypical depression using the HAMD-25 to measure antidepressant efficacy and a DISF subscale (domain I) to measure sexual cognition/fantasy (desire). After treatment, a 50% reduction from baseline HAMD-25 score identified antidepressant responders. Item 12 of HAMD scale (psychic anxiety) was used to define anxiolytic response scores of 0, 1 as responders, and scores of 2, 3, and 4 as nonresponders. Gepirone-ER had no significant antidepressant or an anxiolytic effect in study 134006; however, DISF results demonstrate that gepirone-ER improves sexual desire in short term (P=0.043) and long term (P=0.006). Both gepirone-ER antidepressant and anxiolytic responders have statistically significant improved sexual desire. Gepirone-ER antidepressant and anxiolytic nonresponders also show statistically significant improvement. In depressed women, gepirone-ER has three mechanisms of action affecting sexual desire: an antidepressant effect, an anxiolytic effect, and a pro-sexual effect. Gepirone-ER improves sexual desire from the 24th to the 50th percentile according to population norms for the DISF.
    Journal of Sexual Medicine 06/2011; 8(9):2569-81. DOI:10.1111/j.1743-6109.2011.02330.x · 3.15 Impact Factor


Available from